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The problem. The country incidence rate of cutaneous 
leishmaniasis (CL) in Guatemala has increased from 3.14 
per 100,000 inhabitants in 2011 to 6.24 per 100,000 
inhabitants in 2019, (Fig.1) (1), probably due to a 
combination of improved active surveillance (2), climate 
changes (3,4), and occupational activities involving 
continued forest contact (5) among others. A national 
control program has been in place since 2003, but 
continued efforts are generating uneven results for the 
different endemic communities. Nationwide actions for CL 
control include active and passive surveillance, diagnosis 
and treatment offered free of cost by the Ministry of Health 
(MoH) and awareness-raising activities. We explored 
barriers and facilitators of CL control in Guatemala as 
experienced and perceived by service users and providers 
in order to inform evidence-based strategies to strengthen 
CL control in the country.  
Data were collected via focus groups and semi-structured 
interviews with key stakeholders, including local and 
national health personnel and residents of four endemic 
communities. It was analyzed via thematic and content 
analysis using NVIVO qualitative data analysis software.   
Figure 1. Cutaneous Leishmaniasis country incidence rate (2011-
2019). 
 
Scope of the problem. A total of 4,262,387 people are 
estimated to be at risk of contracting CL in Guatemala, 
mostly in six  northern departments (Petén, Alta Verapaz, 
Izabal, Quiché,  Huehuetenango and El Progreso) (6). Alta 
Verapaz, the department where our study was conducted, 
registered 58% of cases in 2019, with an incidence rate of 
72.26 per 100,000 (7). Active surveillance activities are 
scarce and passive surveillance is known to cause  incidence 
underestimation (2), meaning that the actual incidence is 
likely to be much higher. Two thirds of the population in 
endemic areas live below the poverty threshold and half of 
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 them lack access to public health services, which further 
limits diagnosis and treatment (8).  
CL surveillance and control in Guatemala is based on the 
Leishmaniasis program (in Spanish, Programa de 
Leishmaniasis), which is part of the country’s Vector-Borne 
Disease Program (VDP). The CL program is led by one MoH 
official exclusively dedicated to CL control and who, with 
support of national entomological, epidemiological 
surveillance and laboratory diagnosis facilities and staff, is 
responsible for nationwide activities. The remaining 
personnel combine CL control alongside various other 
vector-borne diseases control programs (9). The program 
also benefits from financial and technical assistance from 
Non-Governmental Organizations and the academy, and 
since 2014 has also received economic and technical 
support from PAHO/WHO. 
Our research indicates that limited economic resources 
dedicated to CL control and associated diagnostic and 
treatment supplies shortages negatively impact CL 
detection and treatment. In addition, local health 
personnel rotates frequently and often lack CL training and 
access to the national guidelines for CL prevention and 
control, which further limits policy implementation. With 
regards to the population at risk living in endemic areas, 
misunderstanding of the disease and its cause and long, 
often uncertain, waiting times for diagnosis and treatment 
negatively affect people’s willingness to seek help, as well 
as their trust and reliance on the health care system.  
Procurement problems: From the list of treatment options 
included in the therapeutic guidelines for leishmaniasis in 
the Americas (10) the MoH only uses meglumine 
antimoniate (MA), (11–13) given the scientific evidence of 
high response rates to this drug in Guatemala (14,15). 
Procurement of this drug is subject to long administrative 
procedures that often cause stock shortages in local health 
centers and treatment delays. According to health 
personnel and residents of endemic areas, once diagnosis 
has been established, people can wait from 6 to 12 months 
to receive treatment. This results in treatment dropouts, 
low treatment adherence and community member’s 
reluctance to seek the advice from health professionals. 
 
In addition to negatively affecting procurement and staff 
numbers (and therefore cure rates), the limited funds 
available for CL control also hamper current CL control 
efforts through hindering active and passive surveillance. 
Most notably, this is because health personnel have no 
adequate transport to reach the affected communities as 
frequently as needed. It is often the case that health staff 
end up visiting affected communities for active surveillance 
and treatment by foot or paying local public transport from 
their own pocket.    
 
During focus groups, some residents of all four endemic 
communities also declared walking or investing a 
significant part of their reduced assets to get to the health 
facilities. Many however admitted being unable to do so.  
Lack of preventive measures: Despite current efforts, it is 
necessary to improve and systematize entomological 
surveillance activities to know the distribution of the 
parasite, vector or reservoir, because there is a scarcity of 
information on the cycles of transmission of CL and 
incrimination of vector  and reservoirs species, as well as 
the distribution of parasites in all endemic areas. In 
addition, no targeted educational campaigns take place 
within the affected communities. Preventive measures are 
reduced to awareness-raising conversations held between 
health workers and community residents during active 
surveillance of cases.   
Program evaluation deficiencies: Leishmaniasis control 
guidelines do not mention program monitoring and 
evaluation or indicate evaluation indicators. There are no 
records of the effectiveness, efficiency, and impact of the 
program, which limits targeted improvement measures 
and the identification of policy issues to consider. 
Short- and long-term effects of program limitations. The 
above-mentioned problems obstruct current CL control 
through various overlapping mechanisms. Despite the 
number of people diagnosed to be suffering from CL is high 
and rising (see Fig 1), qualitative information reveals that 
not all affected individuals receive timely treatment.  Both 
in the long and short term: 
“We go to the health services to lose our time  
…because there is no medicine…”.  
Resident of CL endemic area 
“…by foot [it takes] 45 minutes. And if we pay a tuc tuc 
[motorized tricycle] it´s Q15.00 [$2.00 USD]… an extra 
expense we cover from our own pocket”.  
Vector Disease Program officer   
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 Lack of CL training of local health personnel decreases 
both the effectiveness of awareness-raising activities 
and workers’ opportunities to effectively identify CL 
cases during surveillance, adversely affecting infection 
and treatment rates.  
 Procurement difficulties and associated treatment 
shortages negatively affect treatment rates, and push 
people to seek community-based treatments that 
often involve applying battery liquid, nail polish, 
crushed chili, fire and gunpowder directly on the 
ulcers.  
 Treatment with MA is costly, painful and cannot be 
administered to all affected individuals (e.g. pregnant 
and nursing women, children under 12 months, and 
people affected by heart, liver or kidney diseases). This 
unfavorably affects cure rates. People’s fear of painful 
injections also negatively impacts on treatment rates 
as people often refuse to seek the advice of health 
professionals because of fear of the treatment. 
People living with a CL ulcer often experience co-infections, 
shame and aversion due to misunderstandings about the 
cause of the disease and associated stigma. When 
superinfected, active ulcers are extremely painful and 
often limit people’s ability to work. Thus, deteriorate both 
the family and the community´s economy. The 
socioeconomic burden of CL has however not been 
measured in Guatemala. 
Policy recommendations: CL control efforts in Guatemala 
follow the guidelines of three main official operational 
documents (epidemiological surveillance protocols for 
vector-borne diseases, manual of procedures for the 
prevention and control of leishmaniasis, and 
comprehensive health care standards for the first and 
second level). These documents highlight the 
epidemiological characteristics of CL, prevention measures, 
diagnostic procedures and treatment options. They also 
detail responsibilities according to the level of care 
(preventive actions at the first level, identification and 
treatment for the second level, and state follow-up of 
complicated cases at the third level). However, follow up 
and evaluation protocols are not covered in detail in any 
technical documents and, together with CL prevention, 
they are the most unattended activities.   
 
Addressing gaps in the national guidelines is of vital 
importance, as staff training should be based on these 
guidelines, which should also be accessed and consulted 
constantly by health workers. There are however 
important challenges to the implementation of the 
activities recommended in the existing program, mainly 
due to lack of resources, both in terms of funds dedicated 
to CL control and in terms of human resources. Involving 
trained and paid community health workers may help 
overcome these problems. Combining health education, 
vector prevention and control and community 
participation has proved to be effective in preventing and 
controlling CL in various countries (16–18). Regarding the 
above-mentioned procurement and treatment problems, 
thermotherapy has been shown to be more cost-effective 
than MA  to treat CL and to cause fewer side effects (14,19). 
Its inclusion in the national treatment protocols can help 
increase cure rates and reduce program costs, but its use is 
still not implemented as a national strategy.  
 
Summary and call to action: Known CL cases concentrate 
in the northern regions of the country, particularly in Petén 
and Alta Verapaz, where our study was conducted. We 
explored barriers and facilitators of CL control as 
experienced and perceived by health personnel and 
residents of endemic areas in order to inform evidence-
based strategies able to strengthen CL control in the 
country. 
Our research indicates that the main challenges to 
successful CL control in the country can be summarized as: 
staff training needs, transport deficits that limit 
surveillance and treatment, drug procurement and 
associated treatment shortages and delays, absence of 
preventive activities and non-existence of evaluative 
measures. 
 
There has been an improvement in surveillance, diagnosis 
and treatment over the last years, but the real magnitude 
of the problem remains largely unknown. This in turn, 
negatively influences the funding allocated to controlling 
this disease. Providing health workers with transport 
(tricycles for instance) and/or organizing fortnightly buses 
so that people living in endemic communities can reach the 
health centers will help strengthen active and passive 
surveillance. 
 
 There are insufficient and poorly trained personnel at the 
local level, who often lack the necessary resources to carry 
out their work. Ensuring that staff has access to existing 
guidelines and protocols and involving trained community 
health workers in CL efforts could help strengthen active 
surveillance, treatment and cure rates. 
 
The implementation of preventive measures is necessary 
to decrease incidence rates. Updated vector incrimination 
information is needed, and culturally appropriate 
educational materials and actions must be developed. The 
MoH’s Department of Health Promotion and Education 
(PROEDUSA) should produce culturally competent 
informative material in the local language (Q´eqchi´) to 
strengthen prevention, treatment, and to avoid social 
stigma among affected individuals. The incorporation of CL 
educational material within the school curriculum in the 
endemic areas is also recommended. CL audio spots in 
Q´eqchi´ for community radio stations can also help 
strengthen preventive action (20). 
 
The MoH must 
seek measures to 
secure stock of 
supplies as well 
as investigate 
whether 
thermotherapy 
can be 
systematized as 
an alternative 
treatment method. 
 
Finally, programmatic monitoring and evaluative 
interventions are imperative to guarantee the continuous 
improvement of the national CL program and its associated 
activities. 
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